在为复发多发性骨髓瘤进行腹腔透析的患者中使用双特异性抗体
Heng Jiang1, Yagya Ahlawat2, Amir Steinberg2
1Department of Internal Medicine, Westchester Medical Center, Valhalla, NY, USA.
概括
双特异性抗体 (BsAbs) 显示出潜在的复发性/耐药性多发性骨髓瘤 (RRMM) 患者在腹膜透析 (PD). 然而,这种末期病 (ESRD) 患者群体的反应可能是暂时的,需要进一步调查.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 复发性/耐药性多发性骨髓瘤 (RRMM) 带来了挑战,特别是在末期病 (ESRD) 患者中.
- 在接受腹腔透析 (PD) 的RRMM患者中,双特异性抗体 (BsAbs) 的疗效尚未得到充分证实.
研究的目的:
- 评估BsAbs在患有RRMM和ESRD的PD患者的潜在疗效.
- 突出这一特定患者群体的临床过程和治疗结果.
主要方法:
- 一个病例报告详细介绍了72岁的女性在PD上RRMM和ESRD的治疗之旅.
- 连续使用各种疗法,包括辐射,化疗和多种BsAbs (teclistamab,talquetamab).
主要成果:
- 该患者接受了多种疗法,包括BsAbs,显示过渡性反应.
- 尽管最初有效,但对BsAbs的反应并不是持久的,需要调整治疗.
结论:
- BsAbs可能为患有PD的RRMM患者提供治疗选择,但它们的有效性可能是暂时的.
- 进一步的研究对于了解BsAbs的药理动力学,最佳剂量和透析依赖MM患者的长期结果至关重要.
相关概念视频
Hybridoma Technology
13.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K


